1-5 of 5
Lamin Juwara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Open Access
Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller, Barry C. Johnson, Larry Anderson, Larry Rubinstein, Brandon Miller, Deborah F. Wilsker, Katherine V. Ferry-Galow, Richard Piekarz, Jennifer Zlott, Murielle Hogu, Lamin Juwara, Julia Krushkal, Mariam Konaté, Alida Palmisano, Yingdong Zhao, Jerry Collins, Ralph E. Parchment, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (11): 2124–2133.
https://doi.org/10.1158/1078-0432.CCR-24-3049
Published: 03 June 2025
View article titled, A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Open Access
James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P. Chawla, Suzanne George, Shreyaskumar R. Patel, Mary Louise Keohan, Sujana Movva, Geraldine O'Sullivan Coyne, Khanh Do, Lamin Juwara, Brooke Augustine, Seth M. Steinberg, Laura Kuhlmann, S. Percy Ivy, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1200–1208.
https://doi.org/10.1158/1078-0432.CCR-22-2145
Published: 03 April 2023
View article titled, Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
Open the PDF for Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma in another window
Journal Articles

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Open Access
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 279–288.
https://doi.org/10.1158/1078-0432.CCR-21-2480
Published: 15 January 2022
View article titled, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Open the PDF for Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Free
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3834–3844.
https://doi.org/10.1158/1078-0432.CCR-21-0329
Published: 15 July 2021
View article titled, Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Open the PDF for Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Free
Shivaani Kummar, Mark Raffeld, Lamin Juwara, Yvonne Horneffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Ismail Baris Turkbey, Peter Choyke, Anthony J. Murgo, James H. Doroshow, Giovanni Melillo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5123–5131.
https://doi.org/10.1158/1078-0432.CCR-11-0682
Published: 31 July 2011
View article titled, Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Open the PDF for Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors in another window
Includes: Supplementary data